173 simultaneous determinations of serum copper levels (SCL), serum zinc levels (SZL) and copper/zinc ratio (CZR) were made by atomic absorption spectrophotometry in 51 previously untreated lymphoma patients. SCL and ...173 simultaneous determinations of serum copper levels (SCL), serum zinc levels (SZL) and copper/zinc ratio (CZR) were made by atomic absorption spectrophotometry in 51 previously untreated lymphoma patients. SCL and CZR were significantly higher in patients before treatment (mean value 22.97 μmol/L, 1.55, respectively) and in those who did not reach complete remission (mean 21.21 μmol/L, 1.36) as compared with the patients in complete remission (mean 16.36 μmol/L, 1.06) or normal controls (mean 15.67 μmol/L, 0.98). The mean value of SCL and CZR of patients in complete remission did not differ significantly from those of normal controls. Patients in stages HI and IV had higher SCL and CZR (mean 25.15 μmol/L, 1.79) than those in stage Ⅰ and Ⅱ (mean 19.30 μmol/L, 1.16). No significant difference in SZL was observed between the patient groups and normal controls. Thus, SCL and CZR may be used as prognostic indicators for monitoring disease activity and response to therapy in malignant lymphoma.展开更多
文摘173 simultaneous determinations of serum copper levels (SCL), serum zinc levels (SZL) and copper/zinc ratio (CZR) were made by atomic absorption spectrophotometry in 51 previously untreated lymphoma patients. SCL and CZR were significantly higher in patients before treatment (mean value 22.97 μmol/L, 1.55, respectively) and in those who did not reach complete remission (mean 21.21 μmol/L, 1.36) as compared with the patients in complete remission (mean 16.36 μmol/L, 1.06) or normal controls (mean 15.67 μmol/L, 0.98). The mean value of SCL and CZR of patients in complete remission did not differ significantly from those of normal controls. Patients in stages HI and IV had higher SCL and CZR (mean 25.15 μmol/L, 1.79) than those in stage Ⅰ and Ⅱ (mean 19.30 μmol/L, 1.16). No significant difference in SZL was observed between the patient groups and normal controls. Thus, SCL and CZR may be used as prognostic indicators for monitoring disease activity and response to therapy in malignant lymphoma.